COVID-19: Vaccines and Therapeutics
Pfizer released the first data evaluating a COVID-19 vaccine’s safety and effectiveness for children between the ages of 5 and 11.
The Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee by a unanimous vote recommended that the FDA issue an emergency use authorization that would enable COVID-19 vaccine boosters for individuals age 65 and older and those at high risk for severe COVID-19,…
Inspiring nurse joins COVID-19 task force and launches community vaccination team.
As COVID-19 care demands “outstrip resources” at some Idaho hospitals, health care leaders came together to discuss how they are addressing the crisis and reiterate the solution: vaccination.
Saline Health CEO says vaccine strategies must “start with the heart.”
The Centers for Disease Control and Prevention revealed the comparative effectiveness of the three Food and Drug Administration-authorized COVID-19 vaccines, with Moderna’s vaccine deemed most effective at preventing hospitalizations.
The Department of Health and Human Services’ Assistant Secretary for Preparedness and Response announced a major change in the distribution of COVID-19 monoclonal antibody therapies.
The Department of Health and Human Services’ (HHS) Assistant Secretary for Preparedness and Response (ASPR) Sept. 13 announced a major change in the distribution of COVID-19 monoclonal antibody therapies.
The AHA has received a $1 million grant from the Centers for Disease Control and Prevention to continue for one year its efforts to encourage COVID-19 vaccine confidence in the hospital field, clinicians and the public.
A pair of peer-reviewed studies published in the New England Journal of Medicine are affirming the safety and effectiveness of Pfizer’s COVID-19 vaccine, first at six months following a completed, two-dose regimen, and then with boosters.